Abstract The purpose of the present study was to compare the effects of methylnaltrexone (MNTX), a peripherally acting μ opioid receptor (μOR) antagonist, on gastrointestinal (GI) motility in naïve vs. opiate chronically treated guinea pigs in vitro and in vivo. We have used the electrically stimulated muscle twitch contractions of longitudinal muscle-myenteric plexus (LMMP) preparations and total GI transit as measure of GI motility. In LMMP preparations of naïve guinea pigs, MNTX (1-30 μM) induced a significant, dose-response reduction of morphine-induced inhibition of electrically stimulated muscle twitch contractions, with an IC 50 of 9.4 10 −8 M. By contrast, MNTX abolished the inhibitory effect of acute morphine at any concentrations tested (1-30 μM) in the guinea pigs chronically treated with opiates. In vivo, MNTX (10-50 mg s.c.) did not affect GI transit in naïve guinea pigs when administered acutely or for five consecutive days, but reversed the GI transit delay induced by chronic morphine treatment. These findings show that MNTX is effective in reversing opiate-induced inhibition of GI motility acting at peripheral μ opioid receptors, but does not exert a pharmacologic effect on GI transit in the absence of opiate stimulation.
Introduction
Opioid analgesics such as morphine are the mainstay therapy for chronic malignant and nonmalignant pain (Schug et al. 1992 ). However, their administration is often accompanied by central and peripheral adverse effects, including the development of analgesic tolerance, physical dependence, sedation, respiratory depression, and bowel dysfunction (Nestler 2004; Becker et al. 2007 ). Opioid-induced bowel dysfunction (OBD) is a disabling condition characterized by a range of different gastrointestinal (GI) symptoms, including delayed gastric emptying, abdominal discomfort, bloating, gastroesophageal reflux, and constipation (Walsh 1990; Pappagallo 2001; Thorpe 2001; Kurz and Sessler 2003; Panchal et al. 2007; Holzer 2010) . The extreme discomfort due to severe constipation can become a limiting factor in the use of morphine compromising patient compliance and leading to the discontinuation of opiate treatment for pain control (Fallon and Hanks 1999) .
Opioids receptors, including μ, δ, and κ, are distributed throughout the central nervous system and periphery (Mansour et al. 1995; Sternini et al. 2004; Peng et al. 2012) . μ opioid receptors (μORs) are the preferred targets for opiate drugs and mediate the development of OBD, which is predominantly due to the interaction of opiates with μORs in enteric neurons, resulting in inhibition of gastric emptying and alteration of coordinated rhythmic contractions (De Luca and Coupar 1996; Sternini 2001) . μOR antagonists, such as naltrexone and naloxone, attenuate OBD symptoms, but they also reduce opiate-induced analgesia since these agents readily cross the blood-brain barrier, and provoke opioid behavioral withdrawal syndrome (Culpepper-Morgan et al. 1992; Pappagallo 2001) .
By contrast, methylnaltrexone (MNTX) and alvimopan are opioid antagonists capable of selectively acting on peripheral μORs without affecting opiate central effects (DeHavenHudkins et al. 2008) . MNTX is a quaternary N-methyl derivative of naltrexone, in which the addition of a methyl group increases the polarity, reducing the ability to cross the bloodbrain barrier (Brown and Goldberg 1985; Yuan and Israel 2006; Reichle and Conzen 2008) . MNTX preferentially acts at peripheral μORs and has been shown to be effective in ameliorating OBD symptoms without interfering with the central analgesic effect of opiates (Yuan et al. 1996; Deibert et al. 2010 ).
There have been numerous studies describing the pharmacological effects of MNTX on GI motility in vitro in guinea pigs, rodents and humans, and in vivo in rodents, which show its affinity for μOR and its efficacy in blocking opiate effects at peripheral sites without affecting the analgesic effect. Given the variability among species, the purpose of the present study was to compare the effects of MNTX on GI motility in the presence or absence of opiate stimulation and with or without prolonged μOR activation in the same species, using the guinea pig as a model system. We have compared the effect of MNTX on (1) morphine-induced inhibition of electrically stimulated muscle twitch contractions of longitudinal musclemyenteric plexus (LMMP) preparations and (2) GI transit in guinea pigs treated chronically with morphine vs. naïve and normal animals without opiate stimulation. The results obtained from this study support the efficacy of MNTX in reversing morphine-induced inhibitory effect on motility, and show that MNTX is more effective following prolonged compared to acute μOR activation, whereas it has no effect on GI transit in vivo in the absence of opiate stimulation.
Materials and methods

Animals
Animal care and procedures were in accordance with the National Institutes of Health recommendations for the humane use of animals. All experimental procedures were reviewed and approved by the appropriate Animal Care Committees at UCLA Los Angeles, CA, USA. Male albino porcellus guinea pigs (150-250 g) (Hartley; Harlan Labs, San Diego, CA, USA) were used for these studies. Guinea pigs were divided in two groups: (a) animals, which did not receive any treatment or received subcutaneous injection of saline twice a day for 7 days (naïve); and (b) chronically treated animals that received subcutaneous injection of morphine sulfate twice a day for 7 days. Each morphine dose was increased progressively as follows: day 1-2, 10 mg/kg; day 3-4, 20 mg/kg; days 5-6, 40 mg/kg; and day 7, 80 mg/kg as described previously (Patierno et al. 2011) . Animals were euthanized 30 min after the last morphine injection with an overdose of isofluorane (2.0 %v/v) in enclosed glass chamber.
Electrically induced contractile response of longitudinal muscle-myenteric plexus preparations Segments of distal ileum were dissected from naïve and chronically morphine-treated guinea pigs and placed in standard Tyrode solution (in millimolar NaCl, 136.9; KCl 2.7; CaCl 2 1.8; MgCl 2 1.04; NaH 2 PO 4 0.4; NaHCO 3 11.9; glucose 5.5) at 37°C. LMMP preparations were prepared by teasing the longitudinal muscle with the intact myenteric plexus from the underlying circular muscle (Sternini et al. 2000) . Isometric contractions were recorded with a force-displacement transducer. After a 45-min equilibration period, strips were maximally stimulated (60 V, 0.1 Hz, 0.5 ms) using two platinum electrodes with a S44 stimulator (Grass Instrument Co., Quincy, MA). Concentration-response plots for the inhibitory effects of morphine (1 nM-10 μM) on electrically induced contractions were constructed in a non-cumulative fashion in the absence or in the presence of MNTX (100 nM-30 μM). Strips were washed for three 5-min periods after each agonist administration, and contractions were allowed to return to baseline before any subsequent pharmacological treatment. MTNX was left in contact with tissues for at least 20 min before agonist administration.
Concentration-response plots were generated by plotting the percent inhibition of the twitch contraction versus the increasing logarithmic concentrations of morphine for both naïve guinea pigs and animals treated chronically with morphine. Individual concentration-response plots were then generated for each concentration of MNTX (1-30 μM) and plotted. In order to determine the IC 50 , the concentration required to produce a half-maximal inhibition of MNTX, a dose-response curve was constructed by treating LMMP preparations with a single dose of morphine (100 nM) and increasing concentrations of the antagonist MNTX (1 nM to 30 μM). These data were fit to a theoretical sigmoidal binding equation:
, where c is the concentration of MNTX tested, h is the Hill coefficient, and B/B max is the fractional normalized response or percentage inhibition of the twitch contraction. The minimum and maximum values were fixed based on the regression value assigned by Prism (GraphPad ver. 5.0 Software, San Diego, CA). In the case of multiple comparisons, a one-way ANOVA in conjunction with the Bonferroni post hoc test was applied. Significance was set at P < 0.05, and variance was expressed as ± SE.
Gastrointestinal transit GI transit was measured using a non-absorbable tracer fluorescein isothiocyanate-labeled dextran with an average molecular mass of 70 kD (FD70) (Moore 2004; Patierno et al. 2011) . Overnight-fasted control animals (non-treated) or animals chronically treated with morphine (chronic) were gavaged with 200 μL of FD70 dissolved in distilled water (2.5 mg/mL) and were euthanized 90 min later. The entire GI tract, from the stomach to distal colon was excised and divided into 15 segments: stomach, small intestine (divided into 10 segments of equal length), cecum, and colon (3 segments of equal length). The luminal content of each segment was collected, suspended in 1 mL of distilled water, vortexed, and centrifuged. The supernatants were collected and fluorometrically assayed for FD70 concentration using a multiwell fluorescent plate reader (Microplate Fluorescence Reader Flx 800; Bio-Tek, Winooski, VT). The wavelengths for detecting FD70 were 490 nm for excitation and 520 nm for emission; the slit width was 2.5 nm, and the integrated time was 1.0 s. The transit of FD70 along the GI tract was summarized by calculating the geometric center (GC) for the FD70 distribution (Miller et al. 1981) . Control guinea pigs received either different doses of MNTX (10, 25, and 50 mg/kg) 30 min before the gavage or a daily dose of MNTX (25 mg/kg) for five consecutive days.
For chronically morphine-treated guinea pigs, a single dose of 25 mg/kg MNTX s.c. was administered 30 min after the last injection of morphine. Differences between means were analyzed using one-way ANOVA with Bonferroni post hoc test for multiple comparisons. Significance was chosen as P < 0.05 and variance is reported as ± SE.
Drugs
Drugs used in this study were morphine sulfate from Baxter Healthcare Corporation (LA, CA) for in vivo injection, morphine sulfate from Sigma (St Louis, MO) for in vitro use, and MNTX (Wyeth Pharmaceuticals Inc., Philadelphia, and Progenics Pharmaceuticals, Tarrytown, NY). Drugs were dissolved in distilled water or 0.9 % sodium chloride.
Results
Electrically induced contraction in LMMP preparations of the guinea pig ileum Isolated LMMP preparations from either naïve or chronically morphine-treated guinea pigs were stimulated electrically in the presence of increasing morphine concentrations (1 nM-10 μM) with or without MNTX (100 nM-30 μM). In naïve guinea pig LMMP preparations, morphine (1 nM-10 μM) produced a concentration-dependent inhibition of electrically induced twitch contractions (Fig. 1) . MNTX (1-10 μM) had no effect on twitch basal contractions; however, we observed a transient increase in the magnitude of the twitch contraction during the first minute of administration of the highest concentration of MNTX (30 μM) (data not shown). MNTX at the concentration of 1 μM caused a rightward shift of the morphine inhibitory plot, without depression of its maximum response or efficacy (Fig. 1) . With increasing concentrations of MNTX (3-30 μM), the inhibitory effect of morphine was abolished. In order to determine the IC 50 , each single dose of MNTX (1 nM-30 μM) was tested in presence of 100 nM morphine. The inhibition of the twitch contraction induced by 100 nM morphine was significantly reduced by MNTX in a concentration-dependent manner (1 nM-30 μM), with an IC 50 value of 9.4 10 −8 M for MNTX vs. morphine (Fig. 2) .
In animals chronically treated with morphine for 7 days to make them tolerant, the morphine inhibitory concentrationresponse curve was shifted rightward without reduction of the maximum response or efficacy when compared to untreated guinea pig LMMP preparations (Fig. 3) , as previously reported (Chavkin and Goldstein 1984; Sternini et al. 2000) , and it was abolished by MNTX at every concentrations used, even the lowest one (1-30 μM) (Fig. 3) , suggesting increased antagonism following prolonged μOR activation. Administration of MNTX (1-30 μM) had no effect on basal contractions.
Gastrointestinal transit
In the control group, the orally administered fluorescent tracer was rapidly transported within the intestine such that (Fig. 4) , indicating that MNTX has no pharmacological activity in the absence of opiate stimulation.
In contrast, in guinea pigs that were chronically treated with morphine, the distribution of the fluorescent tracer was shifted toward the more proximal segment of the GI tract, indicating a significant delay in GI transit time (3.83 ± 0.50 vs. 9.85 ± 0.46, p < 0.05). Injection of 25 mg/kg of MNTX s.c. significantly reduced this delay of intestinal motility induced by chronic treatment with morphine (Fig. 4) . 
Discussion
In this study, we used the guinea pig as a model system to compare the effect of MNTX on GI motility in vitro and in vivo in normal conditions and following prolonged activation of μORs with morphine. This study showed that the inhibition of the twitch contraction induced by morphine (1 nM-10 μM) was effectively antagonized by MNTX at various concentrations in either naïve or chronically morphine-treated guinea pigs, extending previous observations. It also showed that MNTX antagonism of morphineinduced inhibition of muscle twitch was more effective following prolonged μOR activation compared to acute stimulation. MNTX reversed the total GI transit delay induced by chronic treatment with morphine, whereas it had no effect on transit in naive animals either administered through i.p. or s.c. routes, acutely or chronically.
Morphine and other opiates are the common treatment for cancer-related or non-related chronic pain, despite the many side effects that are limiting factors in pain management (Kurz and Sessler 2003; Nestler 2004; Panchal et al. 2007) . OBD is one of the most distressing adverse effect associated with opiate administration (Kurz and Sessler 2003) and is characterized by a range of GI symptoms, including abdominal pain, bloating, and constipation (Pappagallo 2001; Panchal et al. 2007 ). These symptoms can be so severe to induce patients to discontinue the narcotic therapy (Fallon and Hanks 1999) compromising the management of pain and further lowering the quality of life of these patients. Opioid effects on GI functions are complex and involve μORs localized in neurons of the enteric nervous system. Enteric neurons expressing μORs are functionally distinct and include motor neurons and interneurons of the ascending and descending pathways controlling peristalsis and propulsion as well as secretomotor neurons regulating secretory functions (Bagnol et al. 1997; Ho et al. 2003; Sternini et al. 2004) . Since μORs are coupled to inhibitory Gi/Go proteins, their activation results in the attenuation of neuronal activity by inhibiting neurotransmitter release (Sternini 2001) . Peripheral μORs are the main mediators of OBD symptoms, in particular constipation, thus antagonists preferentially acting at these μORs represent the best approach to reduce GI side effects in patients chronically treated with opiate analgesics. MNTX belongs to this category of drugs and it is characterized by poor lipid solubility resulting in limited ability to cross the blood-brain barrier, with a consequent limited central nervous system activity. MNTX has been extensively tested in different species in both in vivo and in vitro systems and has been shown to be effective in OBD treatment in clinical trials (DeHaven-Hudkins et al. 2008; Viscusi et al. 2009; Garnock-Jones and McKeage 2010) . Interspecies variability needs to be taken into consideration when evaluating the inhibitory effects of opioid antagonists on intestinal motility, which vary from inhibition of propulsion to stimulation of non-propulsive or segmental motility pattern (Greenwood-Van Meerveld et al. 2004) . The purpose of our study was to compare the potency of MNTX in blocking opiate effects on peripheral μORs in the presence or absence of prolonged μOR activation vs. its pharmacological effect in the absence of opiate stimulation in a single species, the guinea pig, which has been extensively used to study opiate actions in the GI tract. The electrically stimulated longitudinal muscle with the myenteric plexus attached from the guinea pig small intestine is one of the most reliable preparations to study the effects of opiates and opioid peptides on cholinergic excitatory neuronal pathways that lead to neurogenic muscle contraction. Morphine inhibition of cholinergic transmission using these preparations has been reproduced in human ileum, making this animal model relevant to Fig. 4 Distribution of FD70 expressed as mean geometric center 90 min after gavage administration in control guinea pigs (white columns) and chronically morphine-treated guinea pigs (black columns). Note the lack of effect of MNTX in naïve animals either administered in single dose via different routes (i.p. and s.c.) and chronically for five consecutive days, and the reversal by a single dose of MNTX of the GI transit delay induced by chronic opiate administration (black columns). ***P < 0.05 vs control; ###P < 0.05 MNTX vs chronic control understand opioid biology in humans. Furthermore, MTNX blocked morphine inhibitory effect in both humans and guinea pig (Yuan et al. 1995) . Moreover, opioid inhibition of cholinergic activity has also been described in human colon (Burleigh and Trout 1986) . A failure of morphine to inhibit cholinergic transmission in human intestine has been reported (Benko et al. 2010) ; however, differences in the experimental protocols, including different frequency and trains of stimulation, might explain the discrepancies in results obtained with similar preparations (Yuan et al. 1995; Benko et al. 2010) . It is also worthy to point out that inhibition of cholinergic transmission is not the only mechanism underlying the in vivo impairment of GI motility and that opioid effects on non-cholinergic-non-adrenergic neurons also play a role in the overall activities of opiates in the gut (Greenwood-Van Meerveld et al. 2004; Sanger and Tuladhar 2004) .
Our data showed that MNTX induced initial contraction of LMMPs probably reflecting an endogenous opioid tone and effectively antagonized the inhibitory effect of morphine on twitch contractions in electrically stimulated LMMPs, confirming previous observations in guinea pig and human isolated ileum (Yuan et al. 1995) . This antagonism was observed in both naïve and chronically treated animals. However, in naïve animals, lower doses of MNTX decreased the morphine inhibitory effect without reducing the maximal response, typical example of competitive antagonism, with abolition of the response to morphine at higher concentrations. By contrast, in tolerant animals, even the lowest concentrations of MNTX completely abolished morphine inhibitory effect on muscle twitch. The increased efficiency of MNTX in blocking morphine effect on LMMP twitch might be due to the reduction of spare receptors (Chavkin and Goldstein 1984) and to the increased efficiency of morphine to induce μOR internalization observed in tolerant animals (Patierno et al. 2011 ). This suggests that in patients treated chronically with opiates, who have developed tolerance, lower doses of MNTX need to be used to block the opiate side effects on GI motility compared to patients receiving acute morphine.
In this study, we analyzed the effect of MNTX on total GI transit using different routes (s.c. and i.p.) and time courses of administration (only one injection or one injection for 5 days) and observed that MNTX did not affect the GI transit in normal animals in the absence of μOR agonists in any of these conditions. Conversely, MNTX reversed morphine-induced peripherally mediated delay of GI transit. These findings are in agreement with previous reports showing efficacy of MNTX as a clinical adjuvant for treatment of chronic pain in patients (Greenwood-Van Meerveld et al. 2004; DeHaven-Hudkins et al. 2008 ) but indicate a lack of direct pharmacologic effect of MNTX on unstimulated μORs. In our study, we focused on the effect of MTNX on the opioid inhibitory activity in the ileum, which develops tolerance to chronic opiate treatment, unlike the colon, which does not become tolerant (Ross et al. 2008) . The colon resistance to tolerance appears to be dependent on ß arrestin 2 (Kang et al. 2012; , an intracellular protein that plays a role in ligand-induced μOR internalization, a process that regulates the ability of the cells to respond to stimulation (Sternini 2001) . Whether MTNX antagonism at μORs varies in different regions of the gut remains to be elucidated. However, MNTX appears to reverse the agonist-induced impairment of GI transit and colorectal transit, indicating a similar effect of MNTX for the small bowel and colon (DeHaven-Hudkins et al. 2008) . The effects of MNTX on opiate-induced inhibition of GI functions are overall similar to those described with Alvimopan, a peripherally acting μOR antagonist, which has also been extensively investigated in different species (DeHaven-Hudkins et al. 2008) . Both compounds selectively antagonize GI functions mediated by μORs, without altering opiate analgesic effects and can reverse opioid inhibition of GI and colorectal transit, though Alvimopam has been reported to be overall more potent that MTNX (Zimmerman et al. 1994; Greenwood-Van Meerveld et al. 2004 ). Alvimopam has also been shown to improve postoperative ileus in rat when administered before surgery, whereas MTNX was not effective (Fukuda et al. 2006 ). Since abdominal surgery induces endogenous opioid release , it has been suggested that Alvimopan amelioration of GI transit delay induced by surgery is mediated in part by inhibition of opioid release (Fukuda et al. 2006 ). However, several trials have now provided strong evidence that both MTNX and Alvimopan facilitate GI transit recovery in patients receiving opioids following abdominal surgery (Viscusi et al. 2009 ).
Whereas, the potency of MNTX on ameliorating the constipating effect of chronic opiates is now well established, it remains to be determined whether MNTX activity is affected by the level of expression and subcellular localization of peripheral μORs. Indeed, the observation of an effect of MNTX on endogenous opioid tone and its different potency on the neurogenic response in tolerant vs. naïve animals might reflect a different level of antagonism. This, in turn, might depend on the subcellular localization of the receptors, which can be affected by intracellular adaptation induced by prolonged receptor activation as well as by stress conditions such as abdominal surgery (Patierno et al. , 2011 . It would also be of interest to determine the efficacy of MNTX on GI motility in conditions of inflammation that have been shown to be accompanied by increased expression of μOR (Philippe et al. 2003 (Philippe et al. , 2006 .
